Veracyte Q2 Revenue Climbs 15% to $150.3M, Swinging to a $25.5M Profit
VCYT has more than doubled off its 52-week low of $22.92 on elevated volume (4.5× avg).
Summary
Veracyte's Q2 2026 revenue rose 15% to $150.3 million, and the company posted a $25.5 million net profit, driven by higher test volumes and improved reimbursement. R&D spending surged 81% as the company invests in its newly launched TrueMRD platform.
Key Events · Earnings and Guidance · VCYT
-
Q2 Revenue and Profit Surge
Total revenue grew 15% YoY to $150.3 million, with testing revenue up 19% to $145.7 million. Net income swung to $25.5 million ($0.31 diluted EPS) from a loss of $1.0 million a year ago.
-
Testing Volume and Pricing Strength
Diagnostic tests reported increased 14% to 48,389, and the company recorded $4.5 million in revenue from prior-period collections, reflecting improved reimbursement and successful appeals.
-
R&D Investment Ramps for TrueMRD
R&D expense jumped 81% to $29.4 million, driven by the assignment of software development costs and increased spending on the TrueMRD platform, which launched during the quarter.
-
Strong Balance Sheet
Cash, cash equivalents, and short-term investments totaled $485.2 million at quarter-end, with no debt. Operating cash flow was $81.0 million for the first six months of 2026.
Analysis · VCYT · Industrial Applications And Services
A strong second quarter saw revenue rise 15% year-over-year to $150.3 million, while net income swung from a loss a year ago to a $25.5 million profit. Testing volume increased 14%, and the company benefited from improved average selling prices and prior-period collections. R&D spending surged 81% as Veracyte invests heavily in its TrueMRD platform, which launched during the quarter. With $485 million in cash and investments and no debt, the company has ample runway to fund this growth. The results confirm the positive pre-announcement from the 8-K filed yesterday, but this 10-Q provides the full financial picture, including balance sheet strength and segment-level detail.
At the time of this filing, VCYT was trading at $46.32 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.7B. The 52-week trading range was $22.92 to $60.91. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.